Takeda enters agreement with F-star Therapeutics to license bispecific antibody
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
List view / Grid view
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
Researchers have developed a two-step approach using whole exome sequencing to focus on genes and pathways that predict whether cancer patients will respond to immunotherapy.
New research has shown that using viral and bacterial vaccine approaches together is safe and far more effective at fighting the cancer than either approach by itself.
Researchers have found that soft-tissue sarcomas change the biology of immune cells surrounding tumours to promote tumour growth
The Mark Foundation for Cancer Research awards ~$12 million to Cancer Grand Challenges Team to develop new immunotherapies for childhood solid tumours.
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
Scientists have demonstrated how killer T cells used in immunotherapy to eliminate cancer cells can also destroy tumour lymphatic vessels, thus greatly reducing the risk of metastasis.
A new study has highlighted that the interferon gamma receptor pathway is necessary for CAR T-cell mediated killing in solid tumours.
Researchers have found that small-molecule activation of innate immunity induces the infiltration of immune cells into cancer cells.
Researchers have identified a previously unrecognised form of hormone therapy-resistant prostate cancer.
Researchers have developed an immunotherapy platform to improve both antitumor immune responses and responses to checkpoint inhibitors
Study in mice significantly slowed liver tumour growth and activated anti-tumour immune response, highlighting an effective immunotherapy for liver cancer.
The new findings could help scientists to identify new targets and develop initial concepts to better restrain the metastatic spread of breast cancer.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.